Rallybio Corp (RLYB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rallybio Corp (RLYB) has a cash flow conversion efficiency ratio of 0.482x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($45.55 Million) by net assets ($94.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RLYB company net worth for the company's overall valuation and market capitalisation.
Rallybio Corp - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Rallybio Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rallybio Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rallybio Corp ranked by their cash flow conversion efficiency. Explore RLYB cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KNH Enterprise Co Ltd
TW:9919
|
-0.038x |
|
Calisa Acquisition Corp Ordinary shares
NASDAQ:ALIS
|
-0.001x |
|
Al-Salam Real Estate Investment Trust
KLSE:5269
|
0.068x |
|
China Aluminum International Engineering Corporation Limited
F:4AI
|
0.088x |
|
Nuveen California Select Tax Free Income Closed Fund
NYSE:NXC
|
-0.014x |
|
Kirloskar Electric Company Limited
NSE:KECL
|
-7.328x |
|
Onano Industrial Corp
TW:6405
|
-0.001x |
|
Centrica PLC
LSE:CNA
|
0.012x |
Annual Cash Flow Conversion Efficiency for Rallybio Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rallybio Corp from 2019 to 2025. View RLYB live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.96 Million | $-29.81 Million | -0.514x | +35.65% |
| 2024-12-31 | $61.65 Million | $-49.28 Million | -0.799x | -40.84% |
| 2023-12-31 | $106.18 Million | $-60.27 Million | -0.568x | -67.75% |
| 2022-12-31 | $169.32 Million | $-57.28 Million | -0.338x | -30.48% |
| 2021-12-31 | $175.60 Million | $-45.53 Million | -0.259x | -60.01% |
| 2020-12-31 | $136.00 Million | $-22.04 Million | -0.162x | +81.82% |
| 2019-12-31 | $16.86 Million | $-15.03 Million | -0.891x | -- |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more